Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019

全身性エリテマトーデス(SLE)治療薬の世界市場

◆タイトル:Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019
◆商品コード:IRTNTR5703
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年4月22日
◆ページ数:83
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、全身性エリテマトーデス(SLE)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、全身性エリテマトーデス(SLE)治療薬の世界市場規模及び予測、治療クラス別分析、種類別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・全身性エリテマトーデス(SLE)治療薬の世界市場:市場規模及び予測
・全身性エリテマトーデス(SLE)治療薬の世界市場:種類別分析
・全身性エリテマトーデス(SLE)治療薬の世界市場:地域別分析
・市場シェア
・購買基準
・市場成長要因
・市場の課題
・市場動向
・競争状況
・主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About SLE
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.

TechNavio’s analysts forecast the Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.
TechNavio’s report, the Global SLE Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it covers the Global SLE Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Anthera Pharmaceuticals
• BMS
• GSK
• ImmuPharma
• Merck Serono
• UCB

[Other Prominent Vendors]
• Amgen
• HGS
• Immunomedics
• Johnson & Johnson
• MedImmune
• Sanofi
• Teva Pharmaceutical Industries

[Market Driver]
• High Prevalence of Autoimmune Disease
• For a full, detailed list, view our report

[Market Challenge]
• Complex Etiology
• For a full, detailed list, view our report

[Market Trend]
• Increase in Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market overview
03.2 Product offerings

04.Market Research Methodology
04.1 Market research process
04.2 Research methodology

05.Introduction

06.Disease Overview
06.1 Etiology
06.2 Epidemiology
06.3 Risk factors
06.4 Quality of life
06.5 Symptoms
06.6 Diagnosis
06.7 Managementand treatment

07.SLE Pipeline Landscape

08.Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 SLE drugs market in Americas
08.3.1 Market size and forecast
08.4 SLE drugs market in Europe
08.4.1 Market size and forecast

09.Market Assessment of Benlysta
09.1.1 Benlysta revenue forecast in US
09.1.2 Benlysta revenue forecast in 5EU
09.2 Five forces analysis

10.Market Segmentation by Type

11.Market Segmentation by Therapeutic Class

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive scenario
20.1.1 Key news
20.1.2 Mergers and acquisitions
20.2 Market share analysis 2014
20.2.1 Anthera Pharmaceuticals
20.2.2 BMS
20.2.3 GSK
20.2.4 ImmuPharma
20.2.5 Merck Serono
20.2.6 UCB
20.3 Other prominent vendors

21.Key Vendor Analysis
21.1 Anthera Pharmaceuticals
21.1.1 Key facts
21.1.2 Business overview
21.1.3 Business strategy
21.1.4 Recent developments
21.1.5 SWOT analysis
21.2 Bristol-Myers Squibb
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Key product offerings
21.2.4 Revenue by geography
21.2.5 Business strategy
21.2.6 Key information
21.2.7 SWOT analysis
21.3 GlaxoSmithKline
21.3.1 Key facts
21.3.2 Business overview
21.3.3 Business segmentation
21.3.4 Business segmentation by revenue 2012 and 2013
21.3.5 Sales by geography
21.3.6 Pipeline products
21.3.7 Business strategy
21.3.8 Key information
21.3.9 SWOT analysis
21.4 ImmuPharma
21.4.1 Key facts
21.4.2 Business overview
21.4.3 Business strategy
21.4.4 Recent developments
21.4.5 SWOT analysis
21.5 Merck Serono
21.5.1 Key facts
21.5.2 Business overview
21.5.3 Geographical segmentation by revenue 2013
21.5.4 Business strategy
21.5.5 Recent developments
21.5.6 SWOT analysis
21.6 UCB
21.6.1 Key facts
21.6.2 Business overview
21.6.3 Product segmentation by revenue 2013
21.6.4 Product segmentation by revenue 2012 and 2013
21.6.5 Geographical segmentation by revenue 2013
21.6.6 Business strategy
21.6.7 Recent developments
21.6.8 SWOT analysis

22.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market research methodology
Exhibit 2: Diagnosed prevalent cases of SLE 2014 and 2019
Exhibit 3: Overview of management of SLE
Exhibit 4: Global SLE drugs market 2014-2019 ($ million)
Exhibit 5: SLE drugs market in Americas 2014-2019 ($ million)
Exhibit 6: SLE drugs market in Europe 2014-2019 ($ million)
Exhibit 7: Benlysta: Global revenue 2011-2013 ($ million)
Exhibit 8: Benlysta: Revenue forecast in US 2014-2019 ($ million)
Exhibit 9: Benlysta:Revenue forecast in 5EU 2014-2019 ($ million)
Exhibit 10: Segmentation of global SLE drugs market by type
Exhibit 11: Segmentation of global SLE drugs market by therapeutic class
Exhibit 12: Segmentation of global SLE drugs market by geography 2014
Exhibit 13: Orencia: Global revenue 2011-2013 ($ million)
Exhibit 14: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 15: Bristol-Myers Squibb: Revenue by geographical segmentation 2013
Exhibit 16: GlaxoSmithKline: Business segmentation 2013
Exhibit 17: GlaxoSmithKline: Business segmentation by revenue 2012 and 2013 (US$ billion)
Exhibit 18: GlaxoSmithKline: Sales by geography 2013
Exhibit 19: GlaxoSmithKline: Pipeline products 2013
Exhibit 20: Merck Serono: Geographical segmentation by revenue 2013
Exhibit 21: UCB: Product segmentation by revenue 2013
Exhibit 22: UCB: Product segmentation by revenue 2012 and 2013 (US$ million)
Exhibit 23: UCB: Geographical segmentation by revenue 2013



【掲載企業】

Anthera Pharmaceuticals Inc, BMS Co, GSK plc, ImmuPharma plc, Merck Serono SA, UCB SA, Amgen, HGS, Immunomedics, Johnson & Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries

【資料のキーワード】

全身性エリテマトーデス(SLE)治療薬、全身性エリテマトーデス(SLE)パイプライン、製薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[全身性エリテマトーデス(SLE)治療薬の世界市場]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆